NiXEN annonces the selling of its minority stake in Labco to Cinven

NiXEN entered Labco’s capital in 2008 as a part of an investment consortium including notably 3i, alongside the company’s founders and independent biologists, in order to support its development and particularly Labco’s ability to be the consolidator of the diagnostics laboratory market in France and Europe.

Labco became a pan-European key player with leadership or co-leadership positions in France, Iberia, Italy and Belgium. More recently the group stepped in the United-Kingdom market, were its development perspectives as a subcontractor for public hospital groups are promising. Since 2008, Labco’s turnover has more than tripled to reach €650m in 2014 through organic growth and more than 100 external acquisitions.

Cinven’s support will allow Labco to pursue the implementation of its medical project and to continue its external growth strategy on fragmented markets.

Contributors:

NiXEN Partners: Philippe Taranto, Anne-Laure Mougenot

Legal advisors:

Weil, Gotshal & Manges LLP: Jean Beauchataud, Charles Cardon, Jean-Baptiste Cornic